Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06703073 · ClinicalTrials.gov registry record · Phase 2
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
A Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, sponsored by PPD Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06703073: Recruiting Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, sponsored by PPD Development.
NCT06703073 is a Phase 2 study of Acute Respiratory Distress Syndrome and ARDS that is actively recruiting participants, run by PPD Development. The registered enrollment target is 600 participants, above the 348-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06703073, a Phase 2 study of Acute Respiratory Distress Syndrome and ARDS, is actively recruiting participants, sponsored by PPD Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments. This record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding intervention-specific records on clinicaltrials.gov listed below in the detailed description.
Conditions Studied
Interventions
- DRUG Cohort A: vilobelimab
- DRUG Cohort A: placebo
- DRUG Cohort B: paridiprubart
- DRUG Cohort B: placebo
- DRUG Cohort C: bevacizumab
Study Locations (20)
California
- Community Regional Medical Center - Fresno
- Long Beach Memorial Medical Center - Long Beach
- University of California Irvine Medical Center - Orange
- University of California Davis Medical Center - Pulmonary Medicine - Sacramento
Florida
- Nova Clinical Research - Bradenton
- North Florida / South Georgia Veterans Health System - Gainesville
- Sarasota Memorial Hospital - Sarasota
Massachusetts
- Tufts Medical Center - Boston
- Lahey Hospital and Medical Center - Burlington
Michigan
- University of Michigan Hospital - Ann Arbor
- Henry Ford Health Hospital - Detroit
Alabama
- University of Alabama Hospital - Birmingham
Colorado
- Denver Health Hospital and Authority - Denver
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Idaho
- St. Luke's Boise Medical Center - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2028-09 |
| Phase | Phase 2 |
What NCT06703073 shows while recruiting
NCT06703073 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 348-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (72% higher).
The record links to 4 conditions, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 5 interventions - of which Cohort A: vilobelimab is the first listed.
NCT06703073 names 20 study sites across 13 states, led by California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06703073 about?
NCT06703073 is a clinical study titled "JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)". This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be random...
What is the current status of trial NCT06703073?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2025-06-10. Estimated completion is 2028-09.
What conditions does trial NCT06703073 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome, ARDS, Acute Respiratory Distress Syndrome (ARDS), ARDS (Acute Respiratory Distress Syndrome).
What interventions are being tested in trial NCT06703073?
The interventions under investigation include: Cohort A: vilobelimab (DRUG), Cohort A: placebo (DRUG), Cohort B: paridiprubart (DRUG), Cohort B: placebo (DRUG), Cohort C: bevacizumab (DRUG).
Who is sponsoring clinical trial NCT06703073?
This trial is sponsored by PPD Development, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06703073 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06703073's enrollment target sits among peer trials
600 5th of 31 higher than 26 of 31 other Acute Respiratory Distress Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Respiratory Distress Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
RECRUITING · Phase 2
-
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI